Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535445 | 0.77 | TSHR (0.48) | IDO1CES2 | |
| SCHEMBL440959 | 0.76 | CES2 (0.58) | IDO1CES2ADRB1MAPTRAPGEF4 | |
| SCHEMBL13863863 | 0.76 | CES2 (0.48) | IDO1CES2SOD1ADRB1MAPT | |
| SCHEMBL3807246 | 0.74 | GABRA1 (0.46) | MAPTRXRARXRBRXRG | |
| SCHEMBL7784269 | 0.74 | IDO1 (0.41) | IDO1CES2SOD1GPR84TDO2 | |
| SCHEMBL24024094 | 0.74 | IDO1 (0.41) | IDO1CES2SOD1SCN9AGPR84 | |
| SCHEMBL10972207 | 0.74 | IDO1 (0.52) | IDO1CES2SOD1GPR84TDO2 | |
| SCHEMBL679095 | 0.74 | ALDH1A1 (0.50) | IDO1CES2SOD1MAPTRXRA | |
| SCHEMBL535527 | 0.74 | CA1 (0.48) | IDO1CES2 | |
| SCHEMBL4600736 | 0.74 | IDO1 (0.41) | IDO1CES2SOD1GPR84TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917239-A1 | FLUOROPROSTAGLANDINS NITRODERIVATIVES | Pfizer, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007000642-A1 | FLUOROPROSTAGLANDINS NITRODERIVATIVES | PFIZER INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-8426631-B2 | Fungicidal compounds, method for the production thereof, and use thereof to combat damaging fungi, and agents comprising the same | BASF SE (DE) | 2013-04-23 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20100304966-A1 | Fungicidal Compounds, Method For the Production Thereof, And Use Thereof To Combat Damaging Fungi, And Agents Comprising The Same | BASF SE (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-1917239-A1 | FLUOROPROSTAGLANDINS NITRODERIVATIVES | Pfizer, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000642-A1 | FLUOROPROSTAGLANDINS NITRODERIVATIVES | PFIZER INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-0930296-B2 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| US-5985920-A | COMPOUNDS FOR TREATMENT OF VISION DEFECTS SUCH AS GLAUCOMA | ASAHI GLASS COMPANY LTD. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5886035-A | PREVENTIVE AND THERAPEUTICAL MEDICINE FOR EYE DISEASE | ASAHI GLASS COMPANY LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0850926-A2 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS COMPANY LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304966-A1 | Fungicidal Compounds, Method For the Production Thereof, And Use Thereof To Combat Damaging Fungi, And Agents Comprising The Same | CYP51A1, ERG28, CAT | IDO1 753/4885CES2 311/4885SOD1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.